Lupin Launches Generic Niaspan® Tablets in the US

              Lupin Launches Generic Niaspan® Tablets in the US

PR Newswire

MUMBAI, India and BALTIMORE, March 21, 2014

MUMBAI, India and BALTIMORE, March 21, 2014 /PRNewswire/ --

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary,
Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets
USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the
United States Food and Drug Administration (FDA) yesterday.

Lupin's Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths
are the AB-rated generic equivalent of AbbVie Inc.'s Niaspan® Tablets 500 mg,
750 mg, 1000 mg and used with diet to reduce elevated TC, LDL-C, Apo B and TG
levels, and to increase HDL-C in patients with primary hyperlipidemia and
mixed dyslipidemia.

Niaspan® Tablets had annual U.S sales of approximately USD 1 billion (IMS MAT
Dec, 2013).

Commenting on the approval Ms. Vinita Gupta, Chief Executive Officer, Lupin
Limited said, "We are happy to launch this product having received approval
from the FDA yesterday. The launch bears testimony to our commitment to
serving our customers and patients by bringing high quality, affordable
medicines to the market."


Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded and generic formulations and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetology,
Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US
(5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by revenues. The Company is also the fastest growing
top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and
Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142
million (USD 242 million) respectively. Please visit
for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated
to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit 


Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Ph: +91-98-20-338-555


SOURCE Lupin Ltd
Press spacebar to pause and continue. Press esc to stop.